Prelude Therapeutics Inc Q2 Loss Misses Estimates

Prelude Therapeutics Inc (PRLD) announced Loss for second quarter that missed the Street estimates.

The company's bottom line totaled -$34.74 million, or -$0.46 per share. This compares with -$30.43 million, or -$0.54 per share, in last year's second quarter.

Analysts on average had expected the company to earn -$0.43 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

Prelude Therapeutics Inc earnings at a glance (GAAP) :

-Earnings (Q2): -$34.74 Mln. vs. -$30.43 Mln. last year.
-EPS (Q2): -$0.46 vs. -$0.54 last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com